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SUMMARY
Red cell distribution width (RDW) is an unconventional biomarker of inflammation. We aimed to explore its 
role as a predictor of treatment response in rheumatoid arthritis (RA).
Eighty-two RA patients (55 females), median age [interquartile range] 63 years [52-69], were selected by 
scanning the medical records of a rheumatology clinic, to analyze the associations between baseline RDW, 
disease activity scores and inflammatory markers, as well as the relationship between RDW changes following 
methotrexate (MTX) and treatment response.
The lower the median baseline RDW, the greater were the chances of a positive EULAR response at three 
months, 13.5% [13.0-14.4] being among those with good response, vs 14.0% [13.2-14.7] and 14.2% [13.5-
16.0] (p=0.009) among those with moderate and poor response, respectively. MTX treatment was followed by 
a significant RDW increase (p<0.0001). The increase of RDW was greater among patients with good EULAR 
response, becoming progressively smaller in cases with moderate and poor response (1.0% [0.4-1.4] vs. 0.7 
[0.1-2.0] vs. 0.3 [-0.1-0.8]; p=0.03).
RDW is a strong predictor of early response to MTX in RA. RDW significantly increases after MTX initiation 
in parallel to treatment response, suggesting a role as a marker of MTX effectiveness.
Key words: Red cell distribution width, rheumatoid arthritis, methotrexate, biomarker.
Reumatismo, 2020; 72 (1): 16-20
n	 INTRODUCTION
Red cell distribution width (RDW) is a measure of the variability in size of 
circulating erythrocytes (1). Recently, it 
has gained popularity as a novel prognos-
tic biomarker: in a prospective cohort of 
middle-aged and older adults, for every 1% 
increment in RDW, all-cause mortality risk 
increased by 22% (2), in line with other 
reports that confirmed the predictive role 
of RDW for cardiovascular (3) and cancer-
related mortality (4).
Among systemic lupus erythematosus 
(SLE) patients, RDW is directly associat-
ed with disease activity and inflammatory 
markers; a normal RDW predicts a better 
response to treatment (5). A higher RDW 
has been reported in patients with systemic 
sclerosis than in healthy controls, marking 
cardiopulmonary involvement (6, 7). Pa-
tients affected by rheumatoid arthritis (RA) 
have a higher RDW than healthy subjects 
(8); a greater RDW is associated with more 
severe disease (9) and predicts cardiovas-
cular events in RA (10). Nevertheless, the 
potential role of RDW in the prediction of 
response to treatment in RA is unexplored. 
In this study, we aimed to evaluate whether 
baseline RDW in RA patients is associ-
ated with early response to methotrexate 
(MTX) treatment.
n	 MATERIALS AND METHODS
We performed a retrospective analysis 
of clinical records of patients affected by 
RA evaluated at the Immunorheumatology 
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Unit of the Maggiore della Carità Hospi-
tal in Novara between 1st January 2010 and 
31st December 2018. 
We included patients who:
1) fulfilled 2010 ACR/Eular classification 
Criteria (11);
2) were not on MTX and were starting 
MTX;
3) had a chemistry panel performed at 
the central laboratory of the Maggiore 
della Carità Hospital in Novara, at the 
beginning of MTX treatment and after 
3 months. 
Concomitant treatments with hydroxychlo-
roquine or low dose prednisone were ad-
mitted. 
The study has been conducted in accord-
ance with the local ethical guidelines. 
Out of 233 records, 45 were discarded be-
cause they presented overlapping charac-
teristics with other rheumatologic diseases 
and 106 because of the unavailability of 
laboratory data at baseline and/or after 3 
months of MTX treatment. Thus, the final 
study population included 82 RA patients.
We recorded demographic, clinical and 
laboratory data at baseline and after treat-
ment. RDW was measured by XN2000 He-
matology Analyzer, Sysmex.
Treatment response was evaluated at the 
follow-up visit at 3-months and graded ac-
cording to EULAR response criteria (12).
Statistical analysis
Data were analyzed by the statistical soft-
ware package MedCalc v.18.10.2 (Med-
Calc Software, Broekstraat 52, 9030, 
Mariakerke, Belgium). For continuous var-
iables, the measures of centrality and dis-
persion of data chosen were medians and 
interquartile ranges [IQR]. 
The correlation between continuous vari-
ables was tested by Spearman’s rank cor-
relation coefficient; the trend for the base-
line RDW and for the RDW variations after 
treatment according to different categories 
of EULAR response were assessed by the 
Jonkheere-Terpstra trend test. We built an 
ROC curve to evaluate the predictive value 
of RDW for a good EULAR response.
Predictors of good EULAR response were 
identified by multivariate logistic regres-
sion analysis; we built two different mod-
els. In the first one, we included RDW and 
Table I - Main demographic and clinical features of the study population. Continuous variables are presented as median [Interquartile 





Moderate and poor responders
(N. 50)
p
Age, years 62.5 [52.0-69.0] 62.5 [51.0-67.5] 63.0 [53.7-69.3] 0.65
Gender, F/M 55 (67.1)/27 (32.9) 21 (65.6)/11 (34.4) 34 (68.0)/16 (32.0) 0.80
Seropositive arthritis (RF and/or ACPA), y/n 58 (70.7)/24 (29.3) 25 (78.1)/7 (21.9) 33 (66.0)/17 (34.0) 0.32
RDW, % 13.9 [13.1-14.8] 13.5 [13.0-14.4] 14.1 [13.3-15.7] 0.01
Hb, gr/dL 13.4 [12.4-14.3] 13.5 [13.0-14.4] 13.0 [12.0-13.9] 0.14
MCV, fl 87.6 [84.5-91.2] 86.3 [83.9-91.3] 88.2 [85.4-91.3] 0.28
CRP, mg/dL 0.82 [0.31-1.73] 0.91 [0.36-1.69] 0.66 [0.25-1.82] 0.48
ESR, mm/h 18 [9-30] 19 [12-32] 16 [8-27] 0.33
DAS28-ESR 4.20 [3.27-5.03] 4.85 [4.19-5.55] 3.51 [2.85-4.69] 0.0002
Methotrexate dose, mg/week 10.0 [10.0-15.0] 10.0 [10.0-15.0] 10.0 [10.0-11.3] 0.44
Steroid, y/n 73 (89.0)/9 (11.0) 28 (87.5)/4 (12.5) 44 (88.0)/6 (12.0) 0.73
Prednisone dose, mg/day 5.0 [5.0-10.0] 5.6 [5.0-10.0] 5.0 [2.5-8.1] 0.20
Hydroxychloroquine, y/n 16 (19.5)/66 (80.5) 7/25 9/40 0.78
Disease duration, months 6 [2-26] 6 [2-19] 8 [2-28] 0.38
F, females; M, males; RF, rheumatoid factor; ACPA, anti-citrullinated protein antibodies; RDW, red cell distribution width; Hb, haemo-
globin; MCV, mean corpuscular volume; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; DAS28-ESR; disease activity 
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the inflammatory markers ESR and CRP; 
in the second one, we included known pre-
dictors of treatment response (RDW, age, 
gender, haemoglobin and prednisone daily 
dose). 
The RDW post-treatment was compared 
with the baseline RDW by the Wilcoxon 
test for paired samples. 
The level of significance chosen for all sta-
tistical tests was 0.05 (two-tailed).
Figure 1 - Baseline RDW according to EULAR response at three 
months. This box & whiskers plot demonstrates the presence of a 
significant trend for baseline RDW according to the EULAR response 
(p=0.008).
Figure 2 - ROC Analysis for RDW.
n	 RESULTS
We selected 82 patients; in Table I we re-
port the main features of the general popu-
lation. At baseline, RDW had no associa-
tion with erythrocyte sedimentation rate 
(ESR) (ρ=0.141, p=0.21), while was in 
direct correlation with C-reactive protein 
(CRP) (ρ=0.258, p=0.02).
After three months of MTX treatment, 
EULAR response was good in 32 (39.0%) 
patients, moderate in 20 (24.4%) and poor 
in 30 (36.5%). RDW was significantly 
lower in patients with a good EULAR re-
sponse (Table I). Moreover, we observed 
a significant trend towards poorer EU-
LAR responses at 3 months in patients 
with larger RDW at baseline (Figure 1; 
RDW 13.5[13.0-14.4] % in patients with 
good EULAR response, 14.0[13.2-14.7] 
% with moderate response and 14.2[13.5-
16.0] % with poor response, respectively; 
p=0.009). 
In Figure 2, we report the ROC curve for 
RDW; a value >13.7% predicts a poor/
moderate response, being 69.4% sensitive 
and 62.5% specific.
At multivariate logistic regression, RDW 
(p=0.02), but not CRP or ESR (p=0.61 
and p=0.38 respectively), was a predic-
tor of a good EULAR response. In a fur-
ther logistic regression model including 
known predictors of EULAR response, 
RDW was the only independent predic-
tor of the 3-months response to MTX 
(1.53[1.01-2.31]; p=0.04); conversely, 
age (1.00[0.97-1.05]; p=0.68), gender 
(1.12[0.37-3.43]; p=0.84), haemoglobin 
(0.88[0.58-1.33]; p=0.54) and prednisone 
daily dose (0.99 [0.95-1.05]; p=0.80) did 
not affect response to treatment.
MTX treatment was followed by an in-
crease of RDW, from 13.9[13.1-14.8] % 
to 14.7[14.0-15.8] % (p<0.0001), while 
haemoglobin levels remained unchanged 
(13.4[13.0-13.6] gr/dL vs. 13.2[12.9-
13.6] gr/dL). The greater the increase in 
RDW, the better was the EULAR response 
(1.0[0.4-1.4] % in good responders vs. 
0.7[0.1-2.0] % in moderate responders 
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n	 DISCUSSION  
AND CONCLUSIONS
In the present study, the two major find-
ings are:
1) a larger baseline RDW is associated 
with poorer treatment response at three 
months;
2) MTX is followed by an increase in 
RDW from baseline: the larger the in-
crease, the better the patient responds 
to MTX.
RDW has been reported to increase in pa-
tients affected by RA and to correlate with 
inflammatory markers (8, 13) and disease 
activity (9). In our cohort, we confirmed 
the association with CRP, but not with 
ESR, in line with a previous study (14). 
This supports the idea that RDW might not 
be merely considered a surrogate biomark-
er of inflammation in patients affected by 
RA; conversely, RDW could be a valuable 
prognostic marker in RA. Indeed, a higher 
RDW at baseline is predictive of a poorer 
response to MTX. This is the first paper re-
porting this finding in RA; similarly a larg-
er RDW predicts poor treatment response 
in SLE (5). The reason why this happens 
might relate to the interference that inflam-
mation has on erythropoiesis, mediated 
by inflammatory cytokines (15). Indeed, 
RDW is positively associated with TNFα 
and IL-6, witnessing that, the higher the 
plasmatic concentration of inflammatory 
cytokines, the larger the impact on eryth-
ropoiesis. In this context, RDW seems far 
more useful than the other inflammatory 
markers, as demonstrated by our logistic 
regression, which confirms that RDW, but 
not CRP and ESR, predicts a good EULAR 
response. 
MTX induces a significant increase in 
RDW, as recently reported by Held et al. 
(16), probably related to the interference of 
the drug with bone marrow activity. Strik-
ingly, the higher the increase of RDW, the 
better the response to treatment. This is 
an apparent paradox; in fact, a more sig-
nificant dampening of inflammatory re-
sponse is paralleled by the development 
of anisocytosis. A possible explanation of 
this finding might be that the variation of 
RDW marks the responsiveness to MTX 
treatment. The impact on erythropoiesis 
could therefore represent a biomarker of 
effectiveness of MTX. Therefore, a smaller 
RDW increase may help to intercept pa-
tients deserving an earlier switch to a more 
aggressive treatment strategy.
Our study is limited by the small sample 
size and by its retrospective design. With 
this caution, RDW is a promising, simple, 
inexpensive and easy to use a novel tool for 
prognostic stratification of RA patients, ca-
pable of identifying patients with a more 
severe disease at baseline and less likely to 
respond to MTX. 
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